CAM
CYTK icon

Capstone Asset Management’s Cytokinetics CYTK Stock Holding History

Capstone Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$238K Buy
+19,660
New +$273K 0.01% 1412

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Capstone Asset Management's CYTK Position: Q2 2017 in Review

Capstone Asset Management opened a new position in Cytokinetics (CYTK) in Q2 2017: 19,660 shares worth $238K. The stake represents 0.01% of the portfolio and ranks #1412 among its holdings.

136 funds tracked by Wall St. Rank hold CYTK as of Q2 2017.

  • Capstone Asset Management held 19,660 shares of Cytokinetics worth $238K as of Q2 2017.
  • Cytokinetics was a new Capstone Asset Management position in Q2 2017.
  • Cytokinetics made up 0.01% of Capstone Asset Management's portfolio in Q2 2017, its #1412 holding.
  • 136 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.